Celgene Says Revlimid Delays Multiple Myeloma (Reuters)


Reuters - Celgene Corp. on Monday said
initial results from two pivotal-stage trials show that its
blood cancer drug Revlimid in combination with chemotherapy
significantly delays progression of multiple myeloma in
relapsed patients.

Read more...